CareRx Corporation

TSX:CRRX 株式レポート

時価総額：CA$204.9m

CareRx 将来の成長

Future 基準チェック /06

CareRxの収益は年間54.6%で減少すると予測されていますが、年間収益は年間4%で増加すると予想されています。EPS は年間12.5%で減少すると予想されています。

主要情報

-54.6%

収益成長率

-12.51%

EPS成長率

Consumer Retailing 収益成長5.7%
収益成長率4.0%
将来の株主資本利益率n/a
アナリストカバレッジ

Good

最終更新日11 May 2026

今後の成長に関する最新情報

Recent updates

ナラティブの更新 • Jun 01

CRRX: Share Repurchases And Higher Future P/E Will Support Upside Potential

Narrative Update on CareRx The average analyst price target for CareRx has shifted from CA$5.38 to CA$5.14. Analysts point to updated fair value estimates, a slightly higher discount rate, more cautious revenue growth assumptions, lower projected profit margins, and a higher future P/E multiple as key drivers of the change.
ナラティブの更新 • May 04

CRRX: Completed Buyback And Stable Assumptions Will Support Long Term Upside

Analysts have nudged their CareRx price target slightly higher to CA$4.50, reflecting modest adjustments to the discount rate, revenue growth assumptions, profit margin outlook and future P/E expectations. What's in the News CareRx completed a share repurchase of 246,069 shares between October 1, 2025 and March 4, 2026, equal to 0.39% of its shares, for a total of CA$0.49 million (Key Developments).
ナラティブの更新 • Apr 19

CRRX: Share Repurchase And Steady Assumptions Will Support Long Term Upside

Analysts have made slight adjustments to their CareRx price targets, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. Their fair value estimate remains steady at CA$4.50.
ナラティブの更新 • Apr 05

CRRX: Share Repurchase And Margin Outlook Will Support Long Term Upside

Analysts have modestly revised their CareRx price target to CA$4.50, reflecting updated assumptions for discount rate, revenue growth, profit margins and future P/E, which keep the fair value estimate steady at CA$4.50. What's in the News CareRx completed a share repurchase of 246,069 shares, representing 0.39% of its shares, for a total of CA$0.49 million under the buyback announced on September 15, 2025 (Key Developments).
ナラティブの更新 • Mar 22

CRRX: Share Repurchases And Higher Assumed P/E Will Support Future Upside

Analysts have adjusted their CA$ fair value estimate for CareRx from about CA$5.08 to roughly CA$5.38, reflecting updated views on revenue growth, profit margins, and future P/E assumptions. What's in the News CareRx completed a share repurchase program, buying back 246,069 shares between October 1, 2025 and March 4, 2026, equal to 0.39% of its shares, for a total of CA$0.49 million (Key Developments).
ナラティブの更新 • Mar 07

CRRX: Improved Profit Outlook And Lower P/E Will Support Future Upside

Analysts have adjusted their CareRx price target slightly higher to CA$5.08 from CA$4.92, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Valuation Changes Fair Value: CA$5.08, up slightly from CA$4.92.
ナラティブの更新 • Feb 21

CRRX: Lower Future P/E Will Support Stronger Shareholder Returns

Analysts have trimmed their target price on CareRx to CA$4.92. They link this move to slightly higher discount rate assumptions and a modestly lower revenue growth outlook, partially balanced by a small improvement in expected profit margins and a lower future P/E estimate.
ナラティブの更新 • Feb 06

CRRX: Refined Earnings Assumptions Will Support Stronger Long Term Upside Potential

Analysts have slightly adjusted their price target on CareRx, citing updated assumptions around revenue growth, profit margins, discount rate and future P/E that fine tune rather than overhaul their previous fair value view. Valuation Changes Fair Value: Unchanged at 4.5x, indicating no shift in the overall valuation anchor used in the model.
ナラティブの更新 • Jan 23

CRRX: Future Earnings Power Will Support Refined Fair Value Upside

Analysts have slightly adjusted their price target on CareRx, reflecting modest tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions. Together these changes point to a more refined view of the company’s fair value around $4.50.
ナラティブの更新 • Jan 09

CRRX: Future Earnings Power Will Drive Repriced Market Expectation

The analyst price target for CareRx has shifted from US$2.25 to US$4.50, with analysts attributing this change to updated assumptions about revenue growth, profitability, and future P/E. What's in the News Between September 15, 2025 and September 30, 2025, CareRx reported no share repurchases under its existing buyback program, with 0 shares repurchased for CAD 0 million in that period (Key Developments).
ナラティブの更新 • Dec 24

CRRX: Higher Future Earnings Multiple Will Drive Stronger Shareholder Returns

Analysts have nudged their price target for CareRx slightly higher, raising it by about $0.06 per share. This reflects modestly stronger expectations for revenue growth and valuation multiples, despite a more cautious view on profit margins.
ナラティブの更新 • Dec 10

CRRX: Upcoming Share Buybacks Will Support Stronger Future Shareholder Returns

Narrative Update on CareRx Analysts have modestly increased their price target on CareRx to reflect a slightly higher valuation multiple and stable expectations for revenue growth and profit margins. This translates into a small upward adjustment in projected equity value by a few cents per share.
ナラティブの更新 • Nov 26

CRRX: Share Repurchase Program Will Drive Stronger Performance Ahead

Analysts have raised their price target for CareRx, increasing the fair value estimate from $4.00 to $4.86. This change reflects improved revenue growth expectations and a more favorable profit margin outlook.
分析記事 • Sep 11

Is CareRx (TSE:CRRX) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
User avatar
新しいナラティブ • Apr 07

North Burnaby Fulfillment Center And European Automation Will Improve Operations

Debt restructuring and cost-saving measures likely increase net margins and improve earnings by reducing interest expenses and operational costs.
分析記事 • Feb 11

Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues

It's not a stretch to say that CareRx Corporation's ( TSE:CRRX ) price-to-sales (or "P/S") ratio of 0.4x right now...
分析記事 • Oct 03

CareRx (TSE:CRRX) Seems To Use Debt Quite Sensibly

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Aug 11

Analyst Estimates: Here's What Brokers Think Of CareRx Corporation (TSE:CRRX) After Its Second-Quarter Report

Last week, you might have seen that CareRx Corporation ( TSE:CRRX ) released its quarterly result to the market. The...
分析記事 • Apr 22

Does CareRx (TSE:CRRX) Have A Healthy Balance Sheet?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
分析記事 • Mar 17

Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues Pushing Shares 28% Higher

CareRx Corporation ( TSE:CRRX ) shares have continued their recent momentum with a 28% gain in the last month alone...
分析記事 • Oct 19

CareRx (TSE:CRRX) Takes On Some Risk With Its Use Of Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
分析記事 • Aug 22

What You Can Learn From CareRx Corporation's (TSE:CRRX) P/S

It's not a stretch to say that CareRx Corporation's ( TSE:CRRX ) price-to-sales (or "P/S") ratio of 0.3x right now...
分析記事 • Sep 22

CareRx (TSE:CRRX) Has A Somewhat Strained Balance Sheet

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • May 14

These 4 Measures Indicate That CareRx (TSE:CRRX) Is Using Debt Extensively

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

業績と収益の成長予測

TSX:CRRX - アナリストの将来予測と過去の財務データ ( )CAD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/2028415830N/A3
12/31/2027406826N/A6
12/31/2026385616337
3/31/2026375272230N/A
12/31/2025370262331N/A
9/30/202536602130N/A
6/30/2025366-22332N/A
3/31/2025367-42836N/A
12/31/2024367-53038N/A
9/30/2024366-63138N/A
6/30/2024367-72734N/A
3/31/2024369-42332N/A
12/31/2023371-51927N/A
9/30/2023374-62533N/A
6/30/2023378-73038N/A
3/31/2023380-341629N/A
12/31/2022382-34922N/A
9/30/2022384-34-411N/A
6/30/2022358-36-510N/A
3/31/2022311-20-18N/A
12/31/2021263-2307N/A
9/30/2021212-2127N/A
6/30/2021187-24-6-3N/A
3/31/2021177-29-20N/A
12/31/2020162-18-20N/A
9/30/2020148-50-3-1N/A
6/30/2020134-47-20N/A
3/31/2020126-34-12N/A
12/31/2019125-46N/A6N/A
9/30/2019122-19N/A3N/A
6/30/2019119-20N/A4N/A
3/31/2019117-39N/A9N/A
12/31/2018119-35N/A7N/A
9/30/201885-27N/A14N/A
6/30/201897-23N/A12N/A
3/31/2018110-3N/A15N/A
12/31/2017122-4N/A16N/A
9/30/2017168-6N/A14N/A
6/30/2017170-3N/A24N/A
3/31/2017170-13N/A10N/A
12/31/2016167-18N/A2N/A
9/30/2016166-21N/A6N/A
6/30/2016166-34N/A3N/A
3/31/2016164-30N/A20N/A
12/31/2015161-35N/A29N/A
9/30/201527-47N/A28N/A
6/30/201560-48N/A22N/A

アナリストによる今後の成長予測

収入対貯蓄率: CRRXの収益は今後 3 年間で減少すると予測されています (年間-54.6% )。

収益対市場: CRRXの収益は今後 3 年間で減少すると予測されています (年間-54.6% )。

高成長収益: CRRXの収益は今後 3 年間で減少すると予測されています。

収益対市場: CRRXの収益 ( 4% ) Canadian市場 ( 4.5% ) よりも低い成長が予測されています。

高い収益成長: CRRXの収益 ( 4% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CRRXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/06/11 03:01
終値2026/06/11 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

CareRx Corporation 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11

アナリスト機関
Kyle McPheeATB Cormark
Kyle McPheeATB Cormark Historical (Cormark Securities)
Doug CooperBeacon Securities Limited